Summary for 2012
Summary for May
Date:Friday May 11, 2012
Title:Melanoma whole-genome sequencing
Abstract:Researchers find mutations of PREX2, a gene associated with breast cancer, in about 14 percent of melanomas. They also find evidence that the rate of mutation is highest in people with a history of chronic sun exposure.
Women with melanoma fare better, stage for stage, than men (09.May.12)
NZ melanoma deaths in 2009 (08.May.12)
NMSC: A systematic review of worldwide incidence (04.May.12)
IARC Review of Human Carcinogens: Radiation (02.May.12)
Summary for April, 2012
Date:Friday Apr 27, 2012
Title:Surgical margins for melanoma in situ
Abstract:Study concludes that the frequently recommended 5-mm margin for melanoma in situ is inadequate. The authors therefore recommend that surgical excision of melanoma in situ should include 9 mm of normal-appearing skin, similar to that for early invasive melanoma.
Anti-cholesterol statins and melanoma risk (24.Apr.12)
UV photographs and melanoma risk (23.Apr.12)
Melanoma in New Zealand Cancer Trends Report (20.Apr.12)
Correlation between sunless tanning products and tanning beliefs and behaviours (16.Apr.12)
MEK1 mutation does not cause BRAF inhibitor resistance in BRAF-mutated melanoma (14.Apr.12)
Ipilimumab in patients with melanoma and brain metastases (11.Apr.12)
Sun-protection behaviours of melanoma survivors (09.Apr.12)
Increasing incidence of melanoma among young adults: US epidemiological study (06.Apr.12)
20-year survival rates for thin melanomas (05.Apr.12)
Summary for March, 2012
Date:Monday Mar 26, 2012
Title:Changes to NCCN melanoma guidelines
Abstract:Updated guidelines include information on vemurafenib (Zelboraf, Plexxikon/Roche) and ipilimumab (Yervoy, Bristol-Myers Squibb) for metastatic disease and a reduced emphasis on testing for metastases in early-stage melanoma.
New NZ research institute to encourage more clinical trials (22.Mar.12)
Sun exposure at work costs Australian employers $38 million (16.Mar.12)
GPs and melanoma diagnosis (15.Mar.12)
New Vitamin D and sun exposure statement (14.Mar.12)
Skin cancer prevention and early detection research priorities (12.Mar.12)
Latest Milestones in Melanocytes/Melanogenesis now live (08.Mar.12)
MelNet’s General Meeting 9 March in Auckland (07.Mar.12)
Roche’s Zelboraf® (vemurafenib) receives New Zealand registration (06.Mar.12)
Sunbeds and increased risk of skin cancer (05.Mar.12)
Summary for February, 2012
Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib (23.Feb.12)
Increased dermatologist density associated with lower melanoma mortality (21.Feb.12)
Leading UK model agencies sign up to 'No Sunbed' policy (19.Feb.12)
Study of sunburn and sun behaviour in adolescence (16.Feb.12)
US website to raise awareness about sun damage and skin cancer (12.Feb.12)
School sun protection policies and practices (10.Feb.12)
View more Postings for February.
Summary for January, 2012
Melanoma patient survival in New Zealand (27.Jan.12)
Contribution of nodular melanoma to mortality (25.Jan.12)
The children and sunscreen study (23.Jan.12)
Trends in melanoma mortality among non-Hispanic whites by educational attainment (19.Jan.12)
Dear 16-year old me (18.Jan.12)
Possible role of oestrogen in melanoma (12.Jan.12)
